Figure 3.

Cinacalcet evoked IJPs were reduced by either PPADS or tropisetron. (A–C) (left panels) show intracellular recordings of IJPs evoked by the CaSR agonist cinacalcet (10 μM). These were indistinguishable from IJPs evoked by L-Phe and shared the same pharmacological profile. PPADS (10 μM) or tropisetron (5-HT₃ and 5-HT₄ receptor antagonist, 10 μM) significantly reduced these IJPs by 60 and 49% respectively (A,B middle panels and histograms). The combination of PPADS and tropisetron was slightly more effective than either antagonist alone (74% reduction, C middle panel and histogram).